H.C. Wainwright analyst Matthew Caufield upgraded Kodiak Sciences (KOD) to Buy from Neutral with a price target of $24, up from $5, after the company reported follow-up data from the Phase 1b APEX trial of KSI-101 in patients with macular edema secondary to inflammation. The data support continued best corrected visual acuity improvement and sustained retinal dryness, the analyst tells investors in a research note. H.C. Wainwright says its retinal work supports the prospects for KSI-101, and broader tarcocimab and KSI-501 retinal development.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Is KOD a Buy, Before Earnings?
- Kodiak Sciences’ KSI-101: Promising Phase 1b Results and Competitive Edge Justify Buy Rating
- Kodiak Sciences reports data from study of KSI-101 in patients with MESI
- Kodiak Sciences’ Phase 3 Trial: A Potential Game-Changer for Macular Edema Treatment
- Kodiak Sciences’ Phase 3 Study on KSI-101: A Potential Game-Changer for Macular Edema